DrugPatentWatch Database Preview
PRAMIPEXOLE DIHYDROCHLORIDE Drug Profile
When do Pramipexole Dihydrochloride patents expire, and what generic alternatives are available?
Pramipexole Dihydrochloride is a drug marketed by Actavis Elizabeth, Anchen Pharms, Dr Reddys Labs Ltd, Macleods Pharms Ltd, Sandoz Inc, Zydus Pharms Usa Inc, Actavis Grp Ptc, Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Barr, Breckenridge Pharm, Glenmark Generics, Mylan, Sandoz, Sciegen Pharms Inc, Strides Pharma, Sun Pharm Inds Inc, Teva Pharms, Torrent Pharms, and Watson Labs. and is included in twenty-five NDAs.
The generic ingredient in PRAMIPEXOLE DIHYDROCHLORIDE is pramipexole dihydrochloride. There are twenty-four drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the pramipexole dihydrochloride profile page.
Summary for PRAMIPEXOLE DIHYDROCHLORIDE
Pharmacology for PRAMIPEXOLE DIHYDROCHLORIDE
| Drug Class | Nonergot Dopamine Agonist Serotonin Reuptake Inhibitor |
| Mechanism of Action | Dopamine Agonists Serotonin Uptake Inhibitors |
Synonyms for PRAMIPEXOLE DIHYDROCHLORIDE
| (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride |
| (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride |
| (6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride |
| (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride |
| (S)-N6-Propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine dihydrochloride |
| (S)-N6-Propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine dihydrochloride |
| (S)-N6-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine Dihydrochloride |
| (S)-Pramipexole Dihydrochloride |
| 104632-25-9 |
| 112GI018 |
| 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, dihydrochloride, (6S)- |
| 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, dihydrochloride, (S)- |
| 4R2HD0M28N |
| 632P259 |
| AB0020076 |
| AB2000575 |
| AC-1040 |
| AC1L3P1Q |
| AK-79154 |
| AKOS005145770 |
| AKOS015844953 |
| AN-15614 |
| ANW-57521 |
| API0005552 |
| BC215599 |
| BG0440 |
| BI-Sifrol |
| C10H19Cl2N3S |
| CCG-220987 |
| CCG-222342 |
| CHEBI:51148 |
| CHEMBL3143955 |
| CS-0890 |
| CTK8B7511 |
| DTXSID90146623 |
| FD7210 |
| FT-0601705 |
| GS-3583 |
| H32P260 |
| HY-17355 |
| J-001210 |
| J-524051 |
| KS-00000GZ2 |
| KS-5081 |
| LS-182448 |
| MFCD00876894 |
| Mirapex |
| Mirapex ER |
| Mirapex LA |
| Mirapexin;Sifrol;Mirapex |
| MolPort-005-938-249 |
| P2073 |
| PNU-98528E |
| PPX dihydrochloride |
| Pramipexole hydrochloride |
| Pramipexole (dihydrochloride) |
| PRAMIPEXOLE 2HCL |
| Pramipexole dihydrochloride [USAN] |
| Pramipexole dihydrochloride, >98% (HPLC), powder |
| PRAMIPEXOLE HYDROCHLORIDE |
| pramipexole hydrochloride anhydrous |
| QMNWXHSYPXQFSK-KLXURFKVSA-N |
| RTC-070954 |
| SC-20191 |
| SC-79550 |
| SCHEMBL42113 |
| SND-919CL2Y |
| SND-919Y |
| ST2402883 |
| ST51051315 |
| TC-070954 |
| UNII-4R2HD0M28N |
| V0817 |
| W-5189 |
US Patents and Regulatory Information for PRAMIPEXOLE DIHYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Generics | PRAMIPEXOLE DIHYDROCHLORIDE | pramipexole dihydrochloride | TABLET;ORAL | 090781-001 | Oct 8, 2010 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Strides Pharma | PRAMIPEXOLE DIHYDROCHLORIDE | pramipexole dihydrochloride | TABLET;ORAL | 202702-001 | Jun 3, 2014 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Actavis Grp Ptc | PRAMIPEXOLE DIHYDROCHLORIDE | pramipexole dihydrochloride | TABLET;ORAL | 091254-003 | Nov 30, 2010 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Zydus Pharms Usa Inc | PRAMIPEXOLE DIHYDROCHLORIDE | pramipexole dihydrochloride | TABLET, EXTENDED RELEASE;ORAL | 202891-001 | Dec 12, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
